

# **PRESCRIBING PATTERNS OF SELECTIVE AND NON- SELECTIVE ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF RHEUMATOID ARTHRITIS**

**Menicksha Beeka**

**A research report submitted to the Faculty of Health Sciences, University of  
Witwatersrand, in partial fulfilment of the requirements for the degree of Master of  
Science in Medicine in Pharmacotherapy  
Johannesburg, 2006**

## **DECLARATION**

I, Menicksha Beeka, declare that this research report is my own work. It is being submitted for the degree of Master of Science in Medicine in Pharmacotherapy in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

.....

..... day of October 2007

## **DEDICATION**

To my family for their encouragement and my friend Dhivendran for his support throughout the research as a whole.

## ABSTRACT

All members registered on the managed care database for the chronic condition Rheumatoid Arthritis (RA), for the period 01 January 2003 to 30 June 2003, were evaluated to determine the prescribing pattern of the cyclo-oxygenase (COX) II inhibitors and non-selective non-steroidal anti-inflammatory (NSAIDs). A total of 2818 members were registered on the managed care database of the chronic condition RA and 1372 members were identified as using COX II inhibitors and 827 members were using non-steroidal anti-inflammatory (NSAIDs). The prescribing frequency determined for the COX II inhibitors were 48.60% and 29.35% for the NSAIDs. The members identified as either using a COX II inhibitor or a NSAIDs were divided into two groups. The prescribing patterns of each group such as age, gender, co-morbid conditions, concomitant medication use and frequency were analysed and compared to the national institute of clinical excellence (NICE) and the South African Rheumatism and Arthritis Association (SARAA) guidelines for the appropriate prescribing of the COX II inhibitors. Celecoxib was the most frequently prescribed COX II inhibitor accounting for 46% of all the COX II inhibitors identified and diclofenac was the most frequently prescribed NSAID accounting for 34% of all the NSAIDs prescriptions. COX II inhibitors were prescribed more frequently to females with a mean age of 55 years than males. A similar prescribing trend was found with the NSAIDs. The COX II inhibitors were frequently prescribed to patients over the age of 56 with co morbid gastro-oesophageal disease and concomitant warfarin and steroid use. The prescribing patterns found in the managed care environment were similar to those recommended by the NICE and SARAA guidelines. The managed care data showed that the COX II inhibitors, which are supposed to have less gastric adverse side effects, were frequently used in combination with gastro-protective agents (GPA's).

This study indicates that even though COX II inhibitors were prescribed more frequently than NSAIDs in the managed care environment the recommended clinical guidelines and protocols employed by the managed care environment were adhered to. However, there

is a need to closely monitor patients on concomitant GPA's treatment and COX II inhibitors.

This study helped to evaluate the current prescribing patterns of COX II inhibitors in the managed health care environment. This study confirmed that guidelines and protocols were adhered to. These are excellent tools to be used in the managed health care environment to ensure effective and appropriate prescribing.

## **ACKNOWLEDGEMENTS**

Thank you to my supervisor, Prof Andries Gous, for his encouragement, guidance and assistance on the research report.

Thank you to Geeneshan Naidoo for his assistance in analysing the statistical data.

Thank you to Discovery Health for giving me the opportunity to use their database of information and to Susan Smith for accessing the data.

<b>TABLE OF CONTENTS</b>	<b>PAGE</b>
DECLARATION	ii
DEDICATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENTS	vi
TABLE OF CONTENTS	vii
LIST OF TABLES	ix
LIST OF FIGURES	x
LIST OF ABBREVIATIONS	xi
<b>1. INTRODUCTION</b>	<b>1</b>
<b>2. MATERIALS AND METHODS</b>	<b>12</b>
2.1 Study objectives	12
2.2 Hypothesis	12
2.3 Methodology	12
<b>3. RESULTS</b>	<b>15</b>
3.1 Total number of the COX II inhibitors and the NSAIDS prescribed	15
3.2 The COX II inhibitors and NSAIDS drug classes	16
3.3 The demographics of the patients identified as using COX II inhibitors and NSAIDS	19
3.4 Co-morbid medical conditions	21
3.5 Current medication use that may increase the risk of GI side effects	24
3.6 Current use of gastro-protective agents	25

<b>4</b>	<b>DISCUSSION</b>	<b>28</b>
4.1	Total number of the COX II inhibitors and the NSAIDS prescribed	28
4.2	The COX II inhibitors and NSAIDS drug classes	28
4.3	The demographics of the patients identified as using COX II inhibitors and NSAIDS	30
4.4	Co-morbid medical conditions, and the use of gastro-protective agents, identified	31
4.4.1	Co-morbid medical conditions	31
4.4.2	Clinically significant GI events and medication use that may increase the risk of GI side effects particularly warfarin and prednisone	32
4.4.3	Current use of gastro-protective agents	33
<b>5.</b>	<b>LIMITATIONS, RECOMMENDATIONS AND CONCLUSION</b>	<b>35</b>
5.1	Limitations	35
5.2	Recommendations	36
5.3	Conclusion	37
	<b>REFERENCES</b>	<b>38</b>
	<b>APPENDICES</b>	
APPENDIX A:	Post-Graduate Committee Research Protocol approval	44
APPENDIX B:	Committee for Research on Human Subjects approval	45
APPENDIX C:	Discovery Health authorisation confirmation	46
APPENDIX D:	List of co-morbid conditions found for RA patients	47



<b>LIST OF TABLES</b>	<b>PAGE</b>
<b>Table</b>	
3.1 Total number of NSAIDs and COX II prescribed for RA	15
3.2 COX II inhibitors drug class	17
3.3 NSAIDs drug class	18

<b>LIST OF FIGURES</b>	<b>PAGE</b>
<b>Figure</b>	
1.1 Council of Medical Schemes algorithm for RA	9
3.1 Percentage of the total number of NSAIDs and COX II inhibitors prescribed for RA	16
3.2 Percentage of the COX II inhibitors prescribed	17
3.3 Percentage of the NSAIDs prescribed	18
3.4 Gender classifications of members receiving COX II inhibitors	19
3.5 Gender classification of members receiving NSAIDs	20
3.6 Age distribution of members prescribed with COX II inhibitors	20
3.7 Age distribution of members prescribed with NSAIDs	20
3.8 Mean ages and gender classification of each member using either COX II inhibitors or NSAIDs	21
3.9 Co-morbid conditions identified for the COX II users	22
3.10 Co-morbid conditions identified for the NSAID users	22
3.11 Comparison of the co-morbid conditions	23
3.12 Age distribution of patients presenting with the co-morbid condition GORD	24
3.13 COX II inhibitor prescribed for patients on concomitant warfarin or steroid therapy	25
3.14 Gastro-protective agents identified	26
3.15 Distribution of gastro-protective agents between the COX II group and the NSAID group	26

## LIST OF ABBREVIATIONS

CABG	Coronary Artery Bypass Surgery
CDL	Chronic Disease List
CLASS	Celecoxib Long-Term Arthritis Safety Study
CMS	Council for Medical Schemes
COX 11	Cyclo-oxygenase inhibitors
CSI	Cox-2 Specific Inhibitor
CSM	Committee on the Safety of Medicines
CV	Cardiovascular
DMARDs	Disease Modifying Agents
DSP	Designated Service Provider
EMA	European Agency for the Evaluation of Medical Products
FDA	Food and Drug Administration
GI	Gastrointestinal
GORD	Gastro-oesophageal reflux disease
GPA's	Gastro-intestinal agents
ICD-10	International classification of Disease, Tenth Edition
MCC	Medicine Control Council
MELISSA	Meloxicam Large-Scale International Study Safety Assessment
NICE	National Institute of Clinical Excellence
NSAIDs	Non-steroidal anti-inflammatory drugs
OA	Osteoarthritis
OTC	Over-the-Counter
PMB	Prescribed Minimum Benefit
RA	Rheumatoid Arthritis
RF	Rheumatoid Factor
SARAA	South African Rheumatism and Arthritis Association
SELECT	Safety and Efficacy Large-Scale evaluation of COX inhibiting therapies
UK	United Kingdom
US	United States
VIGOR	Vioxx Gastrointestinal Outcomes Research
WHO	World Health Organisation